Combined Supplementary Information from Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer

Authors:
  • JGJonathan T. Goldstein
    Jonathan T. Goldstein
  • ABAshton C. Berger
    Ashton C. Berger
  • JSJuliann Shih
    Juliann Shih
  • FDFujiko F. Duke
    Fujiko F. Duke
  • LFLaura Furst
    Laura Furst
  • DKDavid J. Kwiatkowski
    David J. Kwiatkowski
  • ACAndrew D. Cherniack
    Andrew D. Cherniack
  • MMMatthew Meyerson
    Matthew Meyerson
  • CSCraig A. Strathdee
    Craig A. Strathdee

Abstract
Supplementary Methods. Supplementary Figure 1. Somatic alterations in PPARG and RXRA are hallmarks of luminal bladder cancer. Supplementary Figure 2. PPARG pathway is activated by overexpression of RXRA S427F/S427Y, but not other mutant alleles in bladder cancer cells. Supplementary Figure 3. Representation of the effects of ligand-dependent modulation on the PPARG interactome. Supplementary Figure 4. Downregulation of FABP4 protein by treatment of PPARG-activated bladder cancer cell lines by inverse-agonist T0070907. Supplementary Figure 5. Genome engineering scheme for generating reporter cell line. Supplementary Figure 6. Basal expression of FABP4 is reduced by PPARG inverse agonists, but not antagonists. Supplementary Figure 7. Lipid metabolism genes are inhibited by PPARG inverse-agonists. Supplementary Figure 8. PPARG inverse-agonists inhibit proliferation of PPARG activated bladder cancer cell lines in clonogenic assays. Supplementary Figure 9. PPARG inverse-agonists, but not antagonists, inhibit proliferation of PPARG-activated bladder cancer cell lines. Supplementary Figure 10. Somatic alterations in RXRA and PPARG.